# EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction

Study · id `cardio:ct-nct05020704` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05020704](<https://clinicaltrials.gov/study/NCT05020704>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05020704

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT05020704. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-16 (actual); primary completion 2024-06-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT05020704, source copy `cardio:ctgov-nct05020704-2024-04-02`, retrieved 2026-10-26)
- Started: 2022-09-16 (actual) (ClinicalTrials.gov record NCT05020704, source copy `cardio:ctgov-nct05020704-2024-04-02`, retrieved 2026-10-26)
- Primary completion: 2024-06-12 (anticipated) (ClinicalTrials.gov record NCT05020704, source copy `cardio:ctgov-nct05020704-2024-04-02`, retrieved 2026-10-26)
- Completion: 2024-06-12 (anticipated) (ClinicalTrials.gov record NCT05020704, source copy `cardio:ctgov-nct05020704-2024-04-02`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT05020704, source copy `cardio:ctgov-nct05020704-2024-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05020704-2024-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
- Acronym: EMPRESS-MI
- Condition: Myocardial Infarction
- Intervention (Drug): Empagliflozin 10 MG
- Intervention (Drug): Placebo
- Lead sponsor: NHS Greater Glasgow and Clyde
- Lead sponsor class: OTHER
- Collaborator: University of Glasgow
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: NHS Greater Glasgow and Clyde (`cardio:org-nhs-greater-glasgow-and-clyde`)
- Registry lists this organization as a collaborator: University of Glasgow (`cardio:org-university-of-glasgow`)

## Provenance

Content hash: 78f5da9323a45bb5d8952dc7596337d3b7cf4e51d7e83efa8aba99a8241d783a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
